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http://dx.doi.org/10.1016/j.trsl.2015Targeted nucleases are widely used as tools for genome editing. Two years ago the
clustered regularly interspaced short palindromic repeat (CRISPR)-associated Cas9
nuclease was used for the first time, and since then has largely revolutionized the
field. The tremendous success of the CRISPR/Cas9 genome editing tool is powered
by the ease design principle of the guide RNA that targets Cas9 to the desired DNA
locus, and by the high specificity and efficiency of CRISPR/Cas9-generated DNA
breaks. Several studies recently used CRISPR/Cas9 to successfully modulate
disease-causing alleles in vivo in animal models and ex vivo in somatic and induced
pluripotent stem cells, raising hope for therapeutic genome editing in the clinics. In
this review, we will summarize and discuss such preclinical CRISPR/Cas9 gene ther-
apy reports. (Translational Research 2016;168:15–21)Abbreviations:Cas9¼CRISPR-associated protein 9; cccDNA¼ covalently closed circular DNA;
CCR5 ¼ chemokine receptor 5; CFTR ¼ cystic fibrosis transmembrane conductance regulator;
CRISPRs ¼ clustered regularly interspaced short palindromic repeats; crRNA ¼ CRISPR RNA;
Crygc ¼ crystallin, gamma C gene; DMD ¼ Duchenne muscular dystrophy; DSBs ¼ double-
strand breaks; FAH ¼ fumarylacetoacetate hydrolase; HBV ¼ hepatitis B virus; HDR ¼ homol-
ogy-directed repair; HIV ¼ human immunodeficiency virus; HSPCs ¼ hematopoietic stem and
progenitor cells; indels ¼ insertions or deletions; iPSCs ¼ induced pluripotent stem cells; LDL-C
¼ low-density lipoprotein cholesterol; LTRs ¼ long terminal repeats; NHEJ ¼ nonhomologous
end joining; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; RGENs ¼ RNA-guided engi-
neered nucleases; sgRNA ¼ single guide RNA; TALENs ¼ transcription activator-like effector
nucleases; tracrRNA ¼ transactivating CRISPR RNA; ZNFs ¼ zinc finger nucleasesINTRODUCTIONC lustered regularly interspaced short palin-dromic repeats (CRISPRs) are classes ofrepeated DNA sequences that act in concert
with CRISPR-associated (Cas) genes to confer bacterial
and archaeal immunity against foreign invading nucleo-
tides such as phages and plasmid DNA.1 From the 3lth Sciences, ETH Zurich, Zurich,
22, 2015; revision submitted
ublication September 12, 2015.
Institute of Molecular Health Sci-
-Weg 7, HPL, 8093 Zurich,
hz.ch.
erved.
.09.008types of CRISPR/Cas systems identified so far, the
type II system has been studied the most. During this
immune response, the invading DNA first gets cut into
small pieces and incorporated into the CRISPR locus.2
The locus is then transcribed as a single noncoding pre-
cursor CRISPR RNA (pre-crRNA) that gets further pro-
cessed into short stretches of mature crRNA. Together
with a second noncoding RNA, the trans-activating
CRISPR RNA (tracrRNA), the crRNA finally forms a
ribonucleoprotein complex with the endonuclease
Cas9, which recognizes and cuts the invading DNA.2
In 2012, a research team led by Emmanuelle Char-
pentier and Jennifer Doudna adapted the type II
CRISPR system from Streptococcus pyogenes for
genome editing.3 By fusing the crRNA to the tracrRNA
they generated a single guide RNA (sgRNA), which re-
cruits the Cas9 nuclease to specific genomic locations
via standard Watson-Crick base pairing.3,4 The
creation of site-specific double-strand breaks (DSBs)15
Fig 1. CRISPR/Cas9-mediated genome editing. Cas9 recruitment to
the target DNA is mediated by a chimeric single-guide RNA (sgRNA).
It contains a protospacer recognizing the target sequence followed by
protospacer adjacent motif (PAM). Cas9-induced DSBs are repaired
either by NHEJ giving rise to indel mutations or by HDR using a syn-
thetic donor DNA template, which enables the introduction of desired
sequence changes. CRISPR, clustered regularly interspaced short
palindromic repeat; crRNA, CRISPR RNA; DSBs, double-strand
breaks; indel, insertions or deletions; tracrRNA, tracer RNA.
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iting through 2 different mechanisms. First, in the
absence of a homologous DNA template DSBs can be
repaired by nonhomologous end joining (NHEJ), which
is an error-prone process that causes small insertions or
deletions. Second, in the presence of a synthetic repair
template DSBs can be repaired by homology-directed
repair (HDR), which enables the introduction of any
desired base-pair changes (Fig 1).5,6
Before the establishment of RNA-guided engineered
nucleases such as the CRISPR/Cas9, programmable
DNA-binding nucleases such as zinc finger nucleases
(ZNFs) and transcription activator-like effector nucle-
ases (TALENs) were used to edit DNA.7,8 However,
engineering such sequence-specific DNA-binding pro-
teins was time-consuming and challenging, which
significantly hampered the widespread usage of these
techniques. Because of the ease and speed of designing
CRISPR-guided nucleases, the CRISPR/Cas9 system
has quickly evolved to be the most widely used DNA ed-
iting tool, and has fostered a large number of gene edit-
ing studies in a variety of organisms, including
mammalians and primates.9-14 These studies have
raised high hopes for CRISPR/Cas9-mediated gene
therapy, which aims to repair disease-causing alleles
by changing the DNA sequence at the exact locationon the chromosome. In this review, we summarize
recent studies that demonstrate proof-of-concept for
CRISPR/Cas9-mediated gene therapy. The following
2 sections focus on in vivo approaches, which target
cells directly in the zygote or adult animals (Fig 2, A).
Furthermore, ex vivo approaches that aim to modify so-
matic stem or progenitor cells in culture with subse-
quent transplantation back into the patient (Fig 2, B)
have been discussed.
CRISPR/Cas9 zygote editing. Injection of CRISPR/
Cas9 components (Cas9 messenger RNA or protein;
sgRNA; HDR template) into the zygote or early stage
embryo allows modifying the genome in all cells of
the organism, including the germline.12 Thus, this
approach results in permanent changes that can be
passed on to subsequent generations, offering the
possibility to eliminate a genetic disease from an
entire family.
Wu et al were one of the first to use this approach to
repair a disease-causing mutation in the mouse embryo.
They focused on a dominant loss-of-function mutation
in the Crygc gene, which causes cataract, a decrease
in vision because of clouding of the eye lenses.15 The
authors injected Cas9 mRNA and the sgRNA targeting
the dominant Crygc allele into the zygote, leading to
the correction of the mutation, with the wild-type allele
on the homologous chromosome acting as a template.
Another study that used CRISPR/Cas9-mediated
genome editing in the mouse embryo corrected a muta-
tion in the gene dystrophin, responsible for inherited
disease, X-linked Duchenne muscular dystrophy
(DMD).16 In this case, the authors injected the Cas9
mRNA and specific sgRNA together with a single-
stranded DNA oligo into the zygote and achieved
HDR from the exogenous DNA template. Although
the authors only obtained partially corrected mosaic
mice because of the editing occurring after the zygote
stage, selective advantage of the corrected skeletal mus-
cle cells still led to a complete rescue of the phenotype.
In a very recent study, Liang et al have also demon-
strated the possibility of CRISPR/Cas9-mediated
zygote editing in human embryos,14 generating contro-
versy among scientists and in the public.17,18 The
reported study used tripronuclear human zygotes to
modify hemoglobin beta, the gene responsible for the
blood disorder b-thalassemia. The researchers,
however, found that the procedure led to a high
number of additional unwanted modifications (off-
target effects), arguing against the use of the current
technique for clinical applications. Moreover, because
existing methods in prenatal diagnostics such as
genetic profiling after in vitro fertilization already
offer a less risky alternative for selecting against
offspring with inborn diseases, we think that germline
Fig 2. In vivo and ex vivo strategies for CRISPR/Cas9-based gene therapies. (A) In in vivo approaches, CRISPR/
Cas9 components are directly delivered into the patient using either viral or nonviral vectors for in situ gene edit-
ing. (B) In ex vivo approaches, genes are edited in patient-derived cells. These can be generated by reprogramming
(iPSCs) or direct expansion of somatic stem/progenitor cells, and are transplanted back into the same patient after
the correction. CRISPR, clustered regularly interspaced short palindromic repeat; iPSCs, induced pluripotent stem
cell.
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nonmedically relevant traits to their children. Because
of these safety and ethical concerns we therefore do
not support the legalization of CRISPR/Cas9-based
genome editing studies in human zygotes.
Somatic CRISPR/Cas9-based editing in vivo. One of the
first studies that successfully corrected a genetic disease
in postnatal animals by in vivo CRISPR/Cas9-mediated
genome editing was conducted by Yin et al in a mouse
model for type I tyrosinemia.19 Hereditary type I
tyrosinemia is caused by a deficiency of the enzyme
fumarylacetoacetate hydrolase (FAH), leading to
cytotoxic metabolite accumulation and cell death of
hepatocytes. Through hydrodynamic tail vein injection
the authors delivered vectors encoding for Cas9 and
the specific sgRNA, along with a DNA oligo for HDR
directly into the mouse liver. This resulted in the
correction of the mutant fumarylacetoacetate
hydrolase allele and stabilization of the protein,
leading to reduced hepatocellular toxicity and a rescue
in weight loss of mice. Of note, tyrosinemia might beparticularly suitable for CRISPR/Cas9 gene therapy, as
the initially low repair frequency of 0.4% is
compensated by the positive selection of corrected
hepatocytes.
Another in vivo study focused on the disruption of the
gene encoding for the proprotein convertase subtilisin/
kexin type 9 (PCSK9) in the mouse liver.20 PCSK9 is
secreted into the plasma by hepatocytes, and limits
low-density lipoprotein (LDL) cholesterol uptake and
degradation by functioning as an LDL receptor antago-
nist. Naturally occurring loss-of-function mutations in
PCSK9 therefore decrease blood cholesterol levels. To
mimic this condition, the authors used adenoviral
CRISPR/Cas9 vectors to disrupt PCSK9 in the mouse
liver. This led to a decrease in PCSK9 protein levels,
an increase in hepatic LDL receptor levels, and subse-
quently decreased plasma cholesterol levels. Impor-
tantly, because this approach is based on the
disruption of a gene function by NHEJ, it was possible
to reach editing efficiencies of up to 50%, which might
already be sufficient for clinical application.
Translational Research
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that CRISPR/Cas9-mediated genome editing could
also be used to cure hepatitis B virus (HBV) infection.21
In many patients, HBV infections become chronic and
trigger liver cirrhosis or hepatocellular carcinoma.
Although antiviral therapies for chronic HBV patients
have been developed, they usually fail to completely
eliminate the virus from the liver. This persistence is
because of the high stability of covalently closed circu-
lar DNA (cccDNA) intermediates, which serve as
templates for viral replication. In their study, the authors
modeled chronic HBV infection in mouse livers by
hydrodynamic tail vein injections of HBV expression
vectors. Importantly, coinjection of the CRISPR/Cas9
system targeting the HBV sequence led to vector cleav-
age, and ultimately to a reduction in serum hepatitis B
surface antigen. Because this HBV mouse model did
not produce the actual cccDNA intermediates, the au-
thors eliminated in similar experiments cccDNA of
the duck HBV in a human cell line, supporting the
possibility of complete HBV eradication by genome
editing. Nevertheless, because any residual viral DNA
could potentially renew the infection, for clinical appli-
cations an extremely efficient CRISPR/Cas9 delivery
system would be needed.
In the previously described preclinical studies, proof-
of-concept in vivo CRISPR/Cas9-based gene therapy
was performed in mice. However, to proceed toward
clinical studies several hurdles still need to be over-
come. First, methods need to be optimized for efficient
and safe delivery of the CRISPR/Cas9 components into
the desired tissues. In the past 25 years, many clinical
trials for gene therapy with conventional ectopic over-
expression vectors have been conducted.22,23 These
studies provide promising results for gene delivery
using both viral and nonviral vectors, which could
potentially be adapted to deliver CRISPR/Cas9-based
vectors. Adeno-associated virus shuttle vectors seem
particularly promising because of their high efficiency
in transducing a broad range of cell types and their
low cytotoxicity and immunogenicity. Importantly, a
recent study demonstrated the possibility to pack the
Cas9 nuclease together with the sgRNA into a single
adeno-associated virus particle by using the signifi-
cantly smaller Cas9 protein encoded by Staphylococcus
aureus.24 A second challenge for in vivo CRISPR/Cas9-
based gene therapy is the low efficiency of HDR
compared with NHEJ, which might limit this approach
to therapies where gene functions need to be eliminated,
or where corrected cells gain a competitive advantage
over unrepaired cells. A possible solution to this prob-
lem might be generating single-strand breaks by paired
Cas9 nickases,25 as a recent report has shown that it in-
creases the ratio of HDR compared with NHEJ.26 Thethird hurdle for applying CRISPR/Cas9 in patients is
safety concerns because of off-target effects.27,28
These unintended DSBs at genomic loci that differ
from the target sequence may cause mutations or
chromosomal rearrangements because of religation
between cuts on different chromosomes. Although the
frequency of off-target alterations still remains
controversial, recently developed genome-scale
methods allow unbiased and highly sensitive detection
of unintended DSBs in a bulk cell population.24,29-32
These studies revealed that the number of off-target mu-
tations strongly varies between individual sgRNAs,
from zero to more than 150 sites that are cut at fre-
quencies between 0.03% and 87%. Because even very
low off-target rates could be a problem for in vivo
gene therapy when tumor driver genes are affected, it
will be crucial to enhance CRISPR/Cas9 specificity.
Two recent studies showed that this might be possible
either by adding 2 guanines at the 50 end of the sgRNA33
or by truncating sgRNAs to 17 nucleotides.34 Moreover,
the use of paired Cas9 nickases,35,36 which generate
single-strand breaks rather than DSBs, or the use of
catalytically dead Cas9 (dCas9)-FokI fusion pro-
tein,37,38 which can only cut as a dimer, has been
shown to greatly reduce off-target mutations.
Somatic CRISPR/Cas9-based editing ex vivo. The
ex vivo approach requires protocols for culturing
patient-derived stem/progenitor cells, which can be
transplanted back into the host after genome editing.
In 2007, Takahashi et al39 developed a method for
generating induced pluripotent stem cells (iPSCs)
from human fibroblasts. Importantly, iPSCs can be
infinitely propagated and differentiated into any cell
type of the body, and thereby present a valuable
source for ex vivo gene therapies. Moreover, in the
last few years, researchers have established protocols
to directly expand somatic stem cells in vitro.40-42 As
these protocols do not involve any dedifferentiation
steps, they might provide a presumably safer
alternative to iPSCs.
One of the first proof-of-concept studies for ex vivo
CRISPR/Cas9-based gene therapy was done in iPSCs
and tackled the genetic blood disorder b-thalassemia.43
b-thalassemia is caused by mutations in the hemoglobin
beta gene, which reduce the production of hemoglobin
and thereby trigger anemia. Currently, the only cure
for b-thalassemia is by transplantation of healthy,
donor-derived histocompatible hematopoietic stem
cells. Corrected patient-derived iPSCs, however, might
provide an alternative source for generating transplant-
able hematopoietic stem cells. Xie et al therefore estab-
lished iPSCs from fibroblasts of a patient homozygous
for b-thalassemia and transfected them with CRISPR/
Cas9-based vectors targeted to the disease-causing
Translational Research
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ogous recombination events were identified by selecting
for a cointegrated antibiotic resistance cassette, which
was later excised through transposase-mediated recom-
bination. By using a novel monolayer protocol, cor-
rected iPSCs were then differentiated into fully
functional red blood cell precursors, which in the future
could potentially be used for transplantations.
In a study directed by Hans Clevers, we recently
demonstrated the possibility of CRISPR/Cas9-
mediated genome editing in primary somatic stem cells.
As a model, we used intestinal organoids, which allow
infinite expansion of multipotent intestinal stem cells
to correct a prevalent cystic fibrosis-causing allele.44
Cystic fibrosis is a monogenetic disease that originates
from mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR), an ion channel that reg-
ulates epithelial fluid transport. Loss-of-function alleles
lead to an accumulation of mucus in the gastrointestinal
and pulmonary tract, causing a number of symptoms
such as difficulties in breathing and recurrent infections.
In the present study, we first isolated intestinal stem
cells from cystic fibrosis patients, expanded them
in vitro as 3-dimensional organoid cultures, and then
transfected them with CRISPR/Cas9-based vectors tar-
geting the CFTR locus together with a template for
HDR. A puromycin resistance cassette within one of
the introns allowed selection of clones with integration
events. Successful gene correction was further demon-
strated by sequencing and in a CFTR-dependent orga-
noid-swelling assay. Importantly, in our study, we
could detect only very few off-target effects.
Two independent studies, moreover, used CRISPR/
Cas9 to correct alleles causing DMD in patient–derived
iPSCs and immortalized cell lines.45,46 DMD is caused
by alterations in the unusually large dystrophin gene,
which encodes for a protein that is important for the
structural integrity of muscle fibers. Loss of gene
function leads to disruptions in muscle fiber structure
and ultimately to a weakening of skeletal, respiratory,
and cardiac muscles. In the first study, Li et al used
CRISPR/Cas9 in combination with a donor template
to restore the full-length dystrophin gene by homolo-
gous recombination in iPSCs derived from DMD pa-
tients that lacked exon 44. Repaired iPSCs were
selected and differentiated into skeletal muscle cells,
in which the wild-type dystrophin protein was
expressed. In the second study, Ousterout et al generated
single and multiple exon deletions to restore the reading
frame of the dystrophin gene in immortalized myoblasts
derived from DMD patients. Importantly, multiplex
gene editing allowed to create a large deletion that
excises exons 45–55, a mutational ‘‘hot spot,’’ harboring
more than 60% of disease-causing DMD mutations.This deletion restored dystrophin expression and func-
tion in vitro and in vivo after transplantation into mutant
mice.
Finally, another ex vivoCRISPR/Cas9-based gene ed-
iting study focused on tackling human immunodefi-
ciency virus (HIV) infection. During its life cycle
HIV-1 integrates into the host genome of immune cells,
where it serves as a template for viral expression. At this
stage, HIVinfection can become transcriptionally silent,
leading to a latent infection. Because the latent virus re-
sides in long-lived cells such as memory T cells, the
infection generally persists indefinitely even in the pres-
ence of potent antiretroviral drugs. Using genome-
editing technologies, researchers are currently testing
2 strategies to tackle latent HIV infection. In the first
approach, the viral genome sequence is targeted by
nucleases to permanently eliminate the integrated HIV
DNA from the genome of infected T cells. Liao et al
recently followed this approach using CRISPR/Cas9
and targeted the highly conserved HIV-1 long terminal
repeats (LTRs) in infected primary CD41T-cells.47 Sta-
ble expression of CRISPR/Cas9-based vectors targeting
the LTR region resulted in their disruption and subse-
quently in reduced virus production and the elimination
of the latent reservoir. In addition, the authors could
demonstrate that HIV reservoir cell types, which had
been generated from human pluripotent stem cells previ-
ously transduced with LTR-targeting CRISPR/Cas9
vectors, were resistant to new HIV infection. In the sec-
ond approach, genome editing is used to convey HIV-1
resistance by modulating chemokine receptor 5
(CCR5), a coreceptor needed for HIV-1 T-cell infection.
Mandal et al48 used CRISPR/Cas9 editing and disrupted
this receptor in CD341 hematopoietic stem and progen-
itor cells (HSPCs). The authors demonstrated the abla-
tion of CCR5 in HSPCs with an efficiency of roughly
30% using CCR5-targeting CRISPR/Cas9 vectors.
Moreover, they reported that these CCR5-ablated
HSPC clones retained full multilineage potential after
xenotransplantation in mice and contained only few
off-target mutations. Importantly, the strategy to mutate
CCR5 has already been performed and successfully
tested in clinical trials using zinc finger nucleases.49
One of the major advantages of ex vivo gene therapy
is the possibility to select and analyze corrected cells.
Thus, only recombinant clones harboring the correctly
edited allele without deleterious off-target mutations
will be chosen for transplantation back into the patient.
Because of this selection step, the efficiency and accu-
racy of the CRISPR/Cas9 system is less critical in
ex vivo approaches compared with in vivo approaches.
On the downside, however, ex vivo editing requires
cell expansion in culture, which can lead to additional
unwanted genomic alterations. In particular, iPSCs are
Translational Research
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tions during reprogramming and expansion.50,51
Although recent studies suggest that growing adult
stem cells in 3-dimensional organoid cultures ensure
higher genetic stability,40 extensive in vitro cell expan-
sion might remain a safety concern. Another hurdle for
ex vivo gene therapy approaches is the efficient ortho-
tropic transplantation of corrected cells. Currently,
cell-based transplantations are well established in the
clinics for hematopoietic stem cells, but in other tissues
such as liver or muscles approaches are still under
development. Nevertheless, despite all the challenges
listed, the CRISPR/Cas9 technology holds immense
promises for bringing gene therapy into the clinics,
and given the tremendous progress that has been made
in the last 2 years, we believe this could happen soon.
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